We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Activated Gut-Homing CD8+ T Cells Evaluated for Celiac Disease Diagnosis

By LabMedica International staff writers
Posted on 10 Nov 2021
Print article
Image: The Immunospot S6 Macro M2 ELISPOT Analyzer (Photo courtesy of Cellular Technology Limited)
Image: The Immunospot S6 Macro M2 ELISPOT Analyzer (Photo courtesy of Cellular Technology Limited)
Celiac disease (CD) is a chronic immune-mediated systemic disease, which is triggered by gluten ingestion in genetically susceptible individuals. Clinical, serological, and histopathological data are used for CD diagnosis.

The diagnosis of celiac disease (CD) in individuals that have started a gluten-free diet (GFD) without an adequate previous diagnostic work-out is a challenge. Several immunological assays such as IFN-γ ELISPOT have been developed to avoid the need of prolonged gluten challenge to induce the intestinal damage.

Clinical Scientists at the Hospital Clínico San Carlos (Madrid, Spain) and their colleagues included in a study a total of 22 CD patients and 48 non-CD subjects, all of them following a GFD, underwent a 3-day 10 gram gluten challenge. Anti-transglutaminase type 2 Anti-(TG2) titers were obtained using a quantitative automated Elia Celikey ELISA (Phadia AB, Freiburg, Germany).

The percentage of two T cell subsets (CD8+ CD103+ β7hi CD38+/total CD8+ and TCRγδ+ CD103+ β7hi CD38+/total TCRγδ+) in fresh peripheral blood drawn baseline and six days after the challenge was determined by flow cytometry. IFN-γ ELISPOT assays were also performed on samples from HLA-DQ2.5 participants. Only patients carrying HLA-DQ2.5 were included for this analysis, which was performed in a subsample of 10 CD patients and 11 non-CD subjects. ROC curve analysis was used to assess the diagnostic performance of the CD8+ T cell response and IFN-γ ELISPOT. All the plates were analyzed using the same spot counting procedure and equipment (Cellular Technology Limited Inc., Cleveland, OH, USA).

The investigators reported that significant differences between the percentage of the two studied subsets of CD8+ and TCRγδ+ cells at days 0 and 6 were found only when considering CD patients. Measuring activated CD8+ T cells provided accurate CD diagnosis with 95% specificity and 97% sensitivity, offering similar results to the IFN-γ ELISPOT. An increased percentage of CD8+ CD103+ β7hi CD38+ T cells after gluten challenge was observed in the patient lacking any HLA risk allele: from 0.003% at day 0 to 0.024% at day 6.

The authors concluded that activated gut-homing CD8+ T cell measurement is a highly accurate blood test for CD diagnosis in patients on a GFD, easily implemented in daily clinical practice. Further multicenter studies on a larger patient sample are warranted to confirm the test diagnostic accuracy, mainly in non-HLA-DQ2.5 subjects. The study was published on October 6, 2021 in the journal BMC Medicine.

Related Links:
Hospital Clínico San Carlos
Phadia AB
Cellular Technology Limited Inc


Gold Supplier
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
Benchtop Centrifuge & Vortexer
ExiSpin
New
Urine Analyzer
R-600S

Print article

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.